

Kesimpta - Kesimpta connect Patient perspectives video - HCP

Prescribing information

Image



Image



Patient "Voice": Perspectives on KesimptaConnect

KESIMPTA®▼ (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.¹

For full safety information, please refer to the <u>KESIMPTA Summary of Product</u> Characteristics (SmPC).1

If you are viewing this video outside of a desktop app, please switch to landscape mode or click the expand button on the right-hand side of the video screen.



KesimptaConnect is a patient support programme developed and funded by Novartis Pharmaceuticals UK Limited. KesimptaConnect is for NHS patients who are receiving KESIMPTA®▼ (ofatumumab) or for whom the decision to prescribe KESIMPTA has been made.

KESIMPTA is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Treatment should be initiated under the guidance of a physician experienced in the management of neurological conditions. Full Prescribing Information and adverse event reporting is available where this video is hosted.

This is a promotional material meant for UK healthcare professionals that is created and funded by Novartis Pharmaceuticals UK Limited.

1. KESIMPTA (ofatumumab) Summary of Product Characteristics.

Adverse Event Reporting:

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gox.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.movartis.com/report or alternatively email mediano-uk@novartis.com/report or alternatively emailto: or call 01276 698370.



UK | September 2024 | FA-11236428



SmPC, summary of product characteristics.

Reference

1. KESIMPTA (ofatumumab) Summary of Product Characteristics.

Image

Safety profile

UK | March 2025 | FA-11213993

Adverse events should be reported. Reporting forms and information can be found at

<u>www.mhra.gov.uk/yellowcard</u>. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at <u>www.novartis.com/report</u>, or alternatively email <u>medinfo.uk@novartis.com</u> or call 01276 698370.

Source URL:

https://www.pro.novartis.com/uk-en/medicines/neuroscience/kesimpta/kesimptaconnect/patient-perspectives-video